RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic

L Tian, T Qiang, C Liang, X Ren, M Jia, J Zhang… - European journal of …, 2021 - Elsevier
The widespread nature of several viruses is greatly credited to their rapidly altering RNA
genomes that enable the infection to persist despite challenges presented by host cells …

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

LP Jordheim, D Durantel, F Zoulim… - Nature reviews Drug …, 2013 - nature.com
Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C

EJ Gane, CA Stedman, RH Hyland… - … England Journal of …, 2013 - Mass Medical Soc
Background The standard treatment for hepatitis C virus (HCV) infection is interferon, which
is administered subcutaneously and can have troublesome side effects. We evaluated …

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus …

E Lawitz, FF Poordad, PS Pang, RH Hyland, X Ding… - The Lancet, 2014 - thelancet.com
Background Interferon-based treatment is not suitable for many patients with hepatitis C
virus (HCV) infection because of contraindications such as psychiatric illness, and a high …

Noninvasive methods to assess liver disease in patients with hepatitis B or C

L Castera - Gastroenterology, 2012 - Elsevier
The prognosis and management of patients with chronic viral hepatitis B and C depend on
the amount and progression of liver fibrosis and the risk for cirrhosis. Liver biopsy …

Current and future therapies for hepatitis C virus infection

TJ Liang, MG Ghany - New England Journal of Medicine, 2013 - Mass Medical Soc
Current and Future Therapies for Hepatitis C Virus Infection | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

Chronic hepatitis C infection

HR Rosen - New England Journal of Medicine, 2011 - Mass Medical Soc
Chronic Hepatitis C Infection | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Direct‐acting antivirals for chronic hepatitis C

JC Jakobsen, EE Nielsen, J Feinberg… - Cochrane database …, 2017 - cochranelibrary.com
Background Millions of people worldwide suffer from hepatitis C, which can lead to severe
liver disease, liver cancer, and death. Direct‐acting antivirals (DAAs), eg sofosbuvir, are …

Preliminary study of two antiviral agents for hepatitis C genotype 1

AS Lok, DF Gardiner, E Lawitz… - … England Journal of …, 2012 - Mass Medical Soc
Background Patients with chronic hepatitis C virus (HCV) infection who have not had a
response to therapy with peginterferon and ribavirin may benefit from the addition of multiple …

APASL consensus statements and recommendation on treatment of hepatitis C

M Omata, T Kanda, L Wei, ML Yu, WL Chuang… - Hepatology …, 2016 - Springer
Abstract The Asian-Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL consensus statements and recommendation on …